Background: For patients with prostate cancer (PCa), the presence of pelvic lymph node metastasis (LNM) is a strong predictor of poor outcome. However, the approaches with promising sensitivity and specificity to detect LNM are still lacking. We investigated the value of collapsin response mediator protein 4 (CRMP4) promoter methylation in biopsies as a predictor for LNM. Methods: CRMP4 promoter methylation at two previously identified CpG sites was determined in 80 case-matched biopsy samples (the training set) using bisulfite pyrosequencing. The predictive cutoff value was independently validated using cohort I of 339 PCa patients (Southern China) and cohort II of 328 case patients (Germany, across China). Mann-Whitney U test, the receiver operating characteristic curve, McNemar's test, and logistic regression were used to assess data. All statistical tests were two-sided. Results: In the training set, CRMP4 promoter methylation (15.0% methylated) was statistically significantly associated with LNM (P < .001). Successful validations were achieved in both cohorts I and II (sensitivity ¼ 92.3%, 95% confidence interval [CI] ¼ 79.3 to 97.9, and sensitivity ¼ 92.2%, 95% CI ¼ 81.1 to 97.8, respectively; specificity ¼ 92.7%, 95% CI ¼ 80.2 to 99.1, and specificity ¼ 91.3%, 95% CI ¼ 87.4 to 94.4, respectively). The sensitivity of CRMP4 promoter methylation is superior to conventional MRI (cohort I: 92.3% vs 26.2%, P < .001; cohort II: 92.2% vs 33.3%, P < .001). CRMP4 promoter methylation is an independent predictor of LNM (cohort I: hazard ratio [HR] ¼ 8.35, 95% CI ¼ 5.64 to 12.35, P < .001; cohort II: HR ¼ 12.46, 95% CI ¼ 5.82 to 26.70, P < .001) in a multivariable analysis model. Conclusion: CRMP4 promoter methylation in diagnostic biopsies could be a robust biomarker for LNM in PCa.
Prostate cancer (PCa) accounts for the second leading cause of male cancer-related deaths in the United States and the sixth worldwide, with more than 250 000 deaths a year (1) . Patients with lymph node-positive PCa have a particularly high risk of recurrence, which was reported to be about 45% for biochemical recurrence and 30% for clinical recurrence at 10 years after radical surgery (2) . Accordingly, patients in this category were shown to have decreased cancer-specific and overall survival (3) (4) (5) . Conventional imaging with CT and MRI is currently used for the detection of lymph node metastases. However, the sensitivity of these techniques is only about 36% because these methods often fail to differentiate between adenopathy caused by inflammation and that related to the deposition of cancer cells (6) . Thus, identification of robust biomarkers in prostate biopsies for accurate prediction of lymph node metastasis is urgently needed.
Emerging evidence shows that DNA methylation plays a crucial role in human carcinogenesis and tumor progression (7, 8) . We have previously shown, for the first time, that the collapsin response mediator protein 4 (CRMP4) acts as a PCa metastasis suppressor. Methylation of two CpG sites within the CRMP4 promoter region (upstream of the transcription start site [UTSS], ie, -848, -841) was found to be critically responsible for downregulation of CRMP4 expression in lymph node metastatic PCa (9, 10) . Herein, we hypothesized that the degree of methylation of DNA at these two CpG sites of the CRMP4 promoter in diagnostic biopsies could be used to delineate the development of lymph node metastasis in PCa. We then prospectively validated the predictive accuracy of CRMP4 promoter methylation in two large independent PCa patient groups.
Methods

Patient Selection and Study Design
This study was approved by the ethics committees of all participating institutions, and all study participants provided written informed consent. The study is registered with www.chictr.org/ cn/, number ChiCTR-DDT-13003134. Patients who met all the following criteria were deemed eligible: 1) those with PCa who underwent open or laparoscopic radical prostatectomy and pelvic lymph node dissection between August 2008 and June 2012. Standard template pelvic lymph node dissections, removing all lymph nodes from the medial inferior margin of the external iliac vein down to the obturator and internal iliac vessels, were performed prior to radical prostatectomy. 2) The pathological results of central pathology review, including biopsies, lymph nodes, and radical prostatectomy specimens, were in accordance with those of the original pathology reports. 3) Sufficient tissue and clinical data for analysis. Exclusion criteria were: receipt of neoadjuvant therapy, radiation, and/or hormonal therapy prior to surgery, and refusal of research consent.
This study had sequential training and validation phases ( Figure 1 ). For the training set, a case-matched cohort of 80 representative biopsy blocks with PCa was obtained from 80 patients from the Third Affiliated Hospital of Sun Yat-sen University. The representative biopsy block was chosen as a block paraffinembedding tumor tissue with the highest pathological Gleason grade according to the modified Gleason grading system after central histologic review of the corresponding slides (11) . Case matching was conducted on a 1:1 basis in an automated fashion using SPSS (version 20.0; SPSS Inc., Chicago, IL) and the following rules: the same clinical T stage, the same biopsy Gleason score, similar preoperative serum prostate-specific antigen (PSA) level (within 5 ng/mL), and similar age at diagnosis (within 15 years). For the independent validation sets, 339 patients in cohort I were prospectively obtained from four hospitals in Southern China. Another 328 patients in cohort II with the same criteria as above were included from Germany and across China (for details, refer to the Supplementary Methods, available online).
Central Histopathological Assessment
All patients underwent at least 10-core transrectal ultrasoundguided biopsies, and at least 10 paraffin blocks per patient were prepared. The biopsy paraffin blocks were available for analysis, and all corresponding hematoxylin-stained, eosin-stained, and immunostained slides were reviewed. All resected lymph nodes were placed on a grid identifying their location and orientation, and subsequently multiple sections of these lymph nodes were stained with hematoxylin and eosin. All cases had undergone a central pathological review before CRMP4 promoter methylation analysis was performed. In detail, all pathological slides and the biopsy, radical prostatectomy, and lymph node specimens were sent to and reviewed by two dedicated uropathologists (D. He and C. K. Shao), who were unaware of the original pathological reports of each patient. In addition, the two uropathologists did not have any information regarding the results from the biopsy specimens of each patient when reviewing the matching radical prostatectomy and lymph nodes specimens. The Gleason pattern was recorded as the central review biopsy and radical prostatectomy Gleason score according to the modified Gleason grading system using the International Society of Urological Pathology consensus (11) . For the biopsy specimens with multiple positive cores, the highest core grade of the given case was recorded. The histopathologic staging was performed according to the Union International Contra Cancer 2002 tumor, node, metastasis (TNM) classification (12) . In cases in which the review diagnosis differed from the diagnosis at the source institution, the samples were further reviewed by another urological pathologist (Z. L. Su), who acted as an arbiter. All review pathologists were unaware of the results of CRMP4 promoter methylation studies.
Bisulfite Pyrosequencing
The selection of the biopsy core for CRMP4 promoter methylation analysis was made by the pathologist conducting the diagnosis, and the core with the highest pathological Gleason grade was selected. Subsequently, the malignant tumor regions were marked and resected using an automatic laser-captured microdissection system (Leica 6500) (13) . Bisulfite pyrosequencing was conducted as per our previous report with some modifications (for details, refer to the Supplementary Methods, available online) (9) .
All methylation analyses were performed in the same laboratory. The technical staff did not have any information regarding tissue diagnosis or patient outcome. All the primers used were summarized in Supplementary Table 1 (available online).
Statistical Analyses
The primary end point was lymph node metastases. Baseline characteristics were presented as percentages for categorical variables and means 6 standard deviation or medians (ranges) for continuous variables. The ability of the frequency of CRMP4 promoter methylation to distinguish cohorts was evaluated by means of descriptive statistics, specifically the Mann-Whitney U test for continuous variables and chi-square test for categorical variables, without correction for multiple comparisons, and receiver operating characteristic (ROC) curves. ROC curves based on the continuously measured CRMP4 promoter methylation frequency were calculated by taking every 0.5% level as a cutoff value then deriving sensitivity and specificity values for the respective cutoff. At each cutoff threshold, the sensitivity against 100% minus specificity was plotted, and the area under the curve (AUC) values that showed the probability of predicting patients with positive lymph nodes from those with negative lymph nodes were calculated. The optimal cutoff thresholds for diagnosis were obtained by Youden index. Briefly, the optimal cutoff threshold values were selected at the point on the ROC curve at which Youden's index (sensitivity þ specificity -1) was maximal (14, 15) . The statistical significance of the sensitivities and specificities of conventional MRI and CRMP4 promoter methylation frequency was calculated using McNemar's test. The association between CRMP4 promoter methylation with the expected cutoff level and lymph node metastasis was assessed using a multivariable logistic regression model after adjusting for clinical parameters (the clinical T stage, the biopsy Gleason score, and preoperative serum PSA levels) in an enter manner. The calibration plot was used to illustrate the level of agreement between CRMP4 promoter methylation predictions and the true risk of lymph node metastases. To determine the clinical value of CRMP4 promoter methylation, decision curve analysis was used to estimate a net benefit for prediction models by summing the benefits (true positives) and subtracting the harms (false positives) (16) . All statistical analyses were performed using SPSS (version 20.0; SPSS Inc, Chicago, IL) or R software version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria), and a two-tailed P value of less than .05 was considered statistically significant.
Results
Training Cohort
The detailed clinicopathological characteristics of the training set were summarized in Supplementary 
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There were no statistically significant differences in preoperative PSA levels, biopsy and pathological Gleason score, clinical and pathological stages between patients with positive lymph nodes and those with negative. The number of removed lymph nodes in the lymph node-positive and lymph node-negative patients was the same. We previously identified two CpG sites in the 5'-flanking sequences of the CRMP4 promoter region using the MethPrimer program (9) . Subsequently, we used bisulfite sequencing polymerase chain reaction (PCR) assay to determine all methylation alleles in prostate epithelial cell line (RWPE1), PCa cell lines (22RV1, CWR-R1, PC3, PC3M, DU145), benign prostatic hyperplasia tissues, localized PCa, and lymph node metastatic PCa tissues. These results showed nine hypermethylation sites (UTSS, -848, -841, -680, -678, -674, -671, -665, -660, and -658). Methylation of two CpG sites (UTSS, -848 and -841) mostly contributed to reduced transcription activity of the CRMP4 promoter in lymph node metastatic PCa tissues, which was consistent with our previous findings (9, 10) . Thus, these two UTSSs were selected for PCR and pyrosequencing. Analysis of 80 samples (lymph node-positive, n ¼ 40; lymph nodenegative, n ¼ 40) in the training cohort confirmed these two UTSSs as part of the most representative area (Figure 2 ).
We used ROC curves to generate the optimum cutoff value for lymph node metastasis detection in the training set (Supplementary Table 2 , available online). There was a statistically significant difference in the median frequency of CRMP4 promoter methylation between patients with positive lymph nodes and those with negative (19.6% vs 4.5%, P < .001). A cutoff value of 15.0% with an area under curve (AUC) of 0.939 (95% confidence intervals [CI] ¼ 0.856 to 0.978) had the highest accuracy (minimal false negative and false positive results; sensitivity ¼ 92.5%, 95% CI ¼ 79.6 to 98.4; specificity ¼ 92.5%, 95% CI ¼ 79.6 to 98.4) (Figure 3 ).
Independent Validation Studies
In cohort I (339 patients from four hospitals) (Table 1) , excellent discrimination was observed between patients with positive lymph nodes and those with negative (AUC ¼ 0.975, 95% CI ¼ 0.958 to 0.989) using the cutoff value of 15.0% (Figure 3) . At a specificity of 92.7% (95% CI ¼ 80.2 to 99.1), a sensitivity of 92.3% (95% CI ¼ 79.3 to 97.9) was established. The positive predictive value (PPV) and negative predictive value (NPV) of CRMP4 Figure 4 ). To confirm that CRMP4 promoter methylation had similar predictive values in different populations, we applied it to the independent validation set of cohort II consisting of 328 patients from seven different centers. There were statistically significant differences in CRMP4 promoter methylation between patients with positive lymph nodes and those with negative (P < .001). At a specificity of 91.3% (95% CI ¼ 87.4 to 94.4), a sensitivity of 92.2% (95% CI ¼ 81.1 to 97.8) was achieved ( Figure 4) . The PPV and NPV of CRMP4 promoter methylation in discriminating between patients with positive lymph nodes and those negative in this cohort were 66.2% (95% CI ¼ 54.0 to 77.0) and 98.4% (95% CI ¼ 96.1 to 99.6), respectively ( Figure 4) . In both cohort I and cohort II, the sensitivity of CRMP4 promoter methylation in discriminating between patients with positive lymph nodes and those with negative is superior to conventional MRI ( 
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of biopsy Gleason score, clinical T stage, and preoperative serum PSA levels in a multivariable analysis model (Table 2) . In both the training set and independent validational cohorts (cohort I and cohort II), CRMP4 promoter methylation showed near-perfect calibration, with the predicted probabilities of lymph node metastases accurately, describing the true risk observed in the cohorts ( Figure 5 ). CRMP4 promoter methylation showed a high net benefit at all threshold probabilities used in common clinical practice according to decision curve analysis ( Figure 6 ). These results also indicate that CRMP4 promoter methylation improves on the current standard of care (all patients undergoing pelvic lymph node dissection).
Discussion
In this study, we developed and validated a novel tool, based on the methylation of two CpG sites of CRMP4 promoter in biopsies, for the prediction of lymph node metastasis in PCa. To our knowledge, the present study used the largest cohort so far applied to show that this tool can successfully discriminate between patients with positive lymph nodes and those with negative. Additionally, CRMP4 promoter methylation status remains a strong independent predictor of lymph node metastases outside of conventional clinicopathological features in a multivariable analysis model. Furthermore, the methylation of these two CpG sites can easily be amplified and the assay can be done in daily clinical practice using routine paraffin-embedded biopsy samples.
For patients with PCa, the presence of pelvic lymph node metastasis is a strong predictor of poor outcome (4, (17) (18) (19) . However, the approaches with promising sensitivity and specificity to detect lymph node metastases are still lacking. Conventional imaging procedures such as CT and standard MRI have very limited ability to predict lymph node involvement as they could only detect enlarged lymph nodes (>8 mm). It seems be a great challenge to accurately distinguish metastases in lymph nodes with the size of 5-8 mm (6, 20) . Recently, using MRI with lymphotropic superparamagnetic nanoparticles to detect lymph node metastases, Heesakkers and colleagues reported a sensitivity of 82% and a specificity of 93% for patients with PCa (6). However, this technique is not yet available in clinical practice, and the application of the complicated imaging techniques is also limited by high costs (21) . Thus, staging systems for PCa that are based on clinical and pathological findings may have reached their limit of the utility in predicting lymph node metastases, but molecular methods could add value (22) .
As PCa is characterized by a low frequency of somatic mutations (23), epigenetic modifications, including aberrant DNA methylation, may have an important role in the disease (24) . DNA methylation is a stable and heritable form of gene silencing. It represents the most robust and readily measurable epigenetic alteration, which is involved in the initiation and metastasis of several kinds of cancer, including PCa (25) (26) (27) . Promoter methylation events could serve as some of the most 
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promising markers for the detection of early occult cancer metastases because DNA-based markers have advantages because of the inherent stability of DNA as compared with RNA and some proteins (28, 29) . Furthermore, the detection of DNA methylation biomarker could be sensitive to 0.1% methylated alleles of a given CpG island locus, which needs only small quantities of DNA, and could be conducted on DNA extracted from paraffin-embedded specimens (30) .
In the present study, CRMP4 promoter methylation in diagnostic biopsies probably indicates the presence of microscopically undetectable micrometastases. The bisulfite pyrosequencing can be sufficiently sensitive to identify a signal of DNA methylation (28, 31) . We found a statistically significant association between CRMP4 promoter methylation status and lymph node metastases in PCa. The well-established optimal cutoff value (15.0%) to predict lymph node metastases by CRMP4 promoter methylation showed high sensitivity and specificity, which was validated in two independent PCa patient groups. Evidence suggests that the constant position of the abnormal CpG methylation in CRMP4 promoter could facilitate a simpler detection procedure than is possible for many common mutations in cancer. These mutations may vary widely from patient to patient in their position within the gene. In contrast, a single assay for detecting promoter methylation status for any given gene (eg, CRMP4) could work in almost all patients (28, (32) (33) (34) . These results, together with our previous findings that the methylation of two CpG sites within the promoter region of CRMP4 is responsible for downregulation of CRMP4 expression in lymph node metastatic PCa (9,10), suggest that CRMP4 promoter methylation status could be a straightforward and robust biomarker of lymph node metastases. Collectively, our findings could be used in current practice by eliminating the need for pelvic lymph node dissection in patients with a negative CRMP4 promoter methylation. For patients with a positive CRMP4 promoter methylation, pelvic lymph node dissection to remove the affected lymph nodes or fine-needle aspiration biopsy to achieve histopathology with minimum surgical effort could be applied. Further research is warranted to address the role of CRMP4 promoter methylation as a surrogate marker for considering early adjuvant treatment (eg, adjuvant radiation) in PCa patients.
Promoter methylation in several other genes, including GSTP1, P16, and RASSF1A, may have utility in improving the sensitivity of PCa diagnosis (35) (36) (37) (38) . We used methylation-specific PCR to identify the methylation status of the promoter region in GSTP1, P16, and RASSF1A for PCa patients. These results showed that the positive rates of promoter methylation in GSTP1, P16, and RASSF1A were 90% (54/60), 20% (12/60), and 83.3% (50/60), respectively. However, there were no statistically significant differences in promoter methylation of GSTP1, P16, and RASSF1A between patients with positive lymph nodes and those with negative (Supplementary Figure 4 , available online).
Our current study is limited because it was almost ethnically homogeneous, although 48 patients from Germany were enrolled in cohort II. Therefore, we cannot make inferences about the effects of race on the value of CRMP4 promoter methylation assay. These results should be further validated in multicenter international clinical trials. Additionally, in China, screening for PCa using serum PSA determination is not routinely and widely performed in practice. Thus, a large proportion of newly diagnosed PCa patients are in the high-risk category (18, 39) . According to the PSA ranges, our study population can be considered a "subscreening" population, and the present findings could be important for those treating similar patient populations.
In summary, our findings show that CRMP4 promoter methylation in diagnostic biopsies, as a robust biomarker for lymph node metastatic PCa with high sensitivity and specificity, was reproducibly confirmed in two large independent validation series. Moreover, this clinical study is the first prospective validation of the test in men from multiple sites across China and Germany. This application would be very useful in managing this challenging patient population that has PCa but, despite negative preoperative staging evaluations, harbors occult metastatic diseases-which, if identified sooner rather than later, have a great potential for prolongation of life if appropriate management is applied. 
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